Core Insights - Tempus AI, Inc. (TEM) is set to report its second-quarter 2025 results on August 8, with an adjusted loss of 24 cents in the last quarter, which was better than the Zacks Consensus Estimate of a loss of 27 cents per share [1] - The company is expected to see significant revenue growth, with the Zacks Consensus Estimate for Q2 revenues at $299.3 million, reflecting an 80.4% increase year-over-year [2] Financial Performance - The earnings estimate for the current quarter is a loss of 23 cents per share, which has narrowed by 4 cents over the past 90 days [2] - Tempus AI experienced a 34.5% gain in Q2 2025, outperforming the broader industry gain of 9.3% and the Medical sector's decline of 3.4% [3][4] Strategic Developments - A significant $200 million partnership with AstraZeneca and Pathos is expected to enhance long-term data monetization for Tempus AI, with revenues from this deal recognized over three years starting in Q2 [6][8] - The hereditary testing segment, bolstered by the acquisition of Ambry Genetics, is projected to continue its growth trend, with a 23% unit increase reported [9] Product Innovations - The company has expanded its diagnostics portfolio with the FDA clearance of its AI-powered ECG tool and the launch of a liquid biopsy assay, which are anticipated to contribute positively to Q2 revenues [10] - Tempus AI is advancing its digital health strategy by integrating its GenAI clinical assistant into EHR systems, which is expected to see strong customer adoption [11] Valuation and Market Position - TEM's stock is currently trading at a forward price-to-sales ratio of 6.86, which is higher than the industry average of 5.80 and other competitors like 10x Genomics and SOPHiA GENETICS [15] - Despite the strong growth potential in the AI market, the company's premium valuation and lack of near-term profitability may limit immediate gains [16][17]

Group 1 - The article suggests that there are opportunities in undervalued stocks that are mispriced by the market as of the end of July [1] - It encourages readers to consider joining a platform for insights on these investment opportunities [1] Group 2 - The article does not provide specific company or industry analysis, focusing instead on general investment advice [2][3][4]

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

SAN DIEGO, July 29, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI's top executi ...

Company Overview - Tempus AI, Inc. has launched xM for treatment response monitoring (TRM), a liquid biopsy assay aimed at detecting molecular responses to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors, enhancing its portfolio of assays for monitoring molecular response and minimal residual disease (MRD) [1][7] - The xM for TRM utilizes a multi-parametric algorithm to assess changes in circulating tumor DNA (ctDNA) from blood samples, allowing for early molecular response evaluation in patients undergoing ICI therapies [3][7] Industry Insights - The increasing incidence of various cancers, including lung, breast, bladder, and cervical cancers, has led to a growing adoption of immune checkpoint inhibitor therapies, which are projected to drive the global immune checkpoint inhibitors market to $154.25 billion by 2030, with a CAGR of 17.9% from 2024 to 2030 [2] - Competitors in the industry, such as Exact Sciences and Guardant Health, are also advancing their product offerings, with Exact Sciences launching new tests for colon cancer screening and molecular residual disease monitoring, while Guardant Health has enhanced its liquid biopsy tests with new applications and comprehensive biomarker testing [4][5] Financial Performance - Tempus AI's stock has seen a significant increase of 91% year-to-date, outperforming the industry growth of 24.1% and the S&P 500's 8.2% improvement [6] - The company's current valuation is high, trading at a forward 12-month Price-to-Sales (P/S) ratio of 7.84X, compared to the industry average of 5.90X [8] Earnings Estimates - Recent projections indicate an improvement in Tempus AI's projected loss per share, with a 2.8% improvement for 2025 and a 12% improvement for 2026 [10]

Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

Core Insights - Class actions have been initiated for investors of Vestis Corporation (NYSE: VSTS) and Tempus AI, Inc. (NASDAQ: TEM) due to alleged misleading statements and undisclosed material facts [1][2][4] Vestis Corporation (NYSE: VSTS) - The class period for Vestis is from May 2, 2024, to May 6, 2025, with a lead plaintiff deadline of August 8, 2025 [2] - Allegations include that defendants made overly positive statements while concealing adverse facts about Vestis' business growth capabilities, particularly regarding customer experience and retention [2] - Following the announcement of poor financial results on May 7, 2025, Vestis withdrew its revenue guidance for fiscal year 2025, leading to a stock price drop from $8.71 to $5.44, a decline of approximately 37.54% in one day [3] Tempus AI, Inc. (NASDAQ: TEM) - The class period for Tempus is from August 6, 2024, to May 27, 2025, with a lead plaintiff deadline of August 11, 2025 [4] - The complaint alleges that Tempus inflated contract values and failed to disclose risks related to its joint venture with SoftBank and its acquisition of Ambry, which had questionable billing practices [4] - A report by Spruce Point Capital Management on May 28, 2025, raised concerns about Tempus' management and financial reporting, leading to a stock price decline from $65.87 to $53.20, a drop of 19.23% [5][6]

Core Viewpoint - Tempus AI, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed material information during the specified Class Period, which has led to significant investor losses [1][3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of certain contract agreements, many of which involved related parties and were non-binding or self-funded [3]. - It is alleged that the joint venture with SoftBank Group Corporation raised credibility concerns due to the appearance of "round-tripping" capital to artificially inflate revenue [3]. - The acquisition of Ambry Genetics Corporation is said to have operated under a business model that relied on aggressive and potentially unethical billing practices, exposing it to regulatory and financial risks [3]. - AstraZeneca PLC reportedly reduced its financial support to Tempus AI through a questionable "pass-through payment" structure involving a joint agreement with Pathos AI, Inc. [3]. - These issues are indicative of broader weaknesses in Tempus AI's core operations and long-term revenue outlook [3]. Group 2: Impact of Research Report - On May 28, 2025, Spruce Point Capital Management, LLC published a research report that raised serious concerns regarding Tempus AI's management, operations, and financial disclosures [4]. - Following the release of this report, Tempus AI's stock price experienced a decline of over 19% [4].

Core Insights - Tempus AI and NVIDIA are both making significant strides in the AI and healthcare sectors, with Tempus AI focusing on precision oncology and NVIDIA leading in AI infrastructure [2][3] - Year-to-date, Tempus AI shares have increased by 91.8%, outperforming NVIDIA's 29.2% gain, indicating strong investor confidence in Tempus AI's growth potential [4] Tempus AI Performance - Tempus AI reported a 75% year-over-year revenue growth in Q1 2025, driven by an 89% increase in genomics revenues and a 31% growth in oncology testing [5][9] - The company is transitioning from diagnostics to developing large-scale AI models, highlighted by a $200 million partnership with AstraZeneca and Pathos to create a significant oncology foundation model [6][9] NVIDIA's Healthcare Initiatives - NVIDIA is enhancing its health tech presence through platforms like Clara and BioNeMo, and partnerships with companies like Novo Nordisk and DCAI to accelerate drug discovery [10][12] - The company is addressing healthcare challenges in Europe by deploying AI solutions to improve patient care and operational efficiency [12] Valuation Comparison - Tempus AI has a forward price-to-sales (P/S) ratio of 7.84, which is below its one-year median of 8.11, while NVIDIA's ratio is 18.96, above its median of 17.81, indicating Tempus AI may be more attractively valued [13] - Analysts suggest a 5.3% upside for Tempus AI based on short-term price targets, compared to a 5.1% upside for NVIDIA [14][16] Final Assessment - Both companies hold a Zacks Rank 3 (Hold), but Tempus AI shows stronger year-to-date gains, faster revenue growth, and a more appealing valuation, making it a potentially better short-term investment in the AI-health tech space [18]

Group 1 - The article highlights the emergence of AI-driven companies like Palantir, Tempus AI, and Recursion Pharmaceuticals as key players in the cancer diagnostics and drug development sectors, contrasting them with traditional pharmaceutical companies [1][2][5] - Palantir's stock has increased nearly 10% month-to-date and has shown significant year-to-date growth, indicating strong investor sentiment ahead of its earnings report [3] - Tempus AI shares are stable at around $64, despite a 6% pullback, reflecting confidence in its genomics-powered diagnostics [3] - Recursion Pharmaceuticals has seen a nearly 15% surge since late June, although it remains down about 10% year-to-date, suggesting renewed optimism in its AI-assisted drug discovery pipeline [4] Group 2 - Traditional pharmaceutical companies like Pfizer and Merck are struggling with stagnant stock prices and challenges such as patent cliffs and rising scrutiny, despite solid revenue [4][6] - In contrast, AI-native companies are redefining the industry by offering innovative solutions: Palantir provides essential data architecture, Tempus delivers actionable diagnostics, and Recursion accelerates drug discovery through machine learning [5] - The article raises the question of whether traditional drugmakers are simply behind in innovation or if they are at risk of becoming obsolete in the evolving healthcare landscape [6]